The FDA is effectively signing the death warrant of more patients by denying them access to Dr. Burzynski’s antineoplaston cancer treatment—for no rational reason whatsoever. Please help. Action Alert!
Over the years, we’ve covered the FDA’s attacks on Dr. Stanislaw Burzynski, the trailblazing cancer doctor best known for his discovery and development of antineoplastons (ANP), which are peptides and amino acid derivatives that activate tumor-suppressing genes. Independent research has confirmedantineoplastons to be an effective cancer treatment.
As we’ve reported in the past, the conventional medical establishment has, through a succession of relentless attacks, slowly choked off patient access to antineoplastons. In July 2012, after years of failed legal attempts to shutter the Burzynski clinic completely, the FDA told Dr. Burzynski he could no longer accept children for treatment with antineoplastons during the current FDA trial. In January 2013, this ban was extended to adults. This means that under current FDA restrictions, no new patients can be treated with antineoplastons. Terminal cases who could be saved will instead die.
Since the FDA has formally forbidden new patient access to antineoplastons, the only hope of dying patients is to convince the FDA to grant a “compassionate use” or “single-patient protocol”exemption via its expanded access rule. This rule allows for the case-by-case use of an experimental or unapproved drug outside of a clinical trial if a patient has a serious or immediately life-threatening disease or condition, and has no other treatment options left.